IP Library Granted Patent US 7,884,120
Granted Patent B2
US 7,884,120 · App. 10/525,690 · Granted Feb 8, 2011

2,4,5-trisubstituted imidazoles and their use as anti-microbial agents

Assignee: Lorus Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,884,120
App. No.
10/525,690
Granted
Feb 8, 2011
Kind
B2
Abstract

The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity.

Claims (45)

1. A compound having the structural formula:

or a salt thereof, wherein:

R4, R5, R6, R7, R8 and R9 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, or cyano;

R10 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or acyl;

x is CR11;

y is CR12;

z is CR13;

r is CR14;

x′ is CR15;

y′ is CR16;

z′ is CR17;

r′ is CR18;

R11, R12, R14, R15, R16 and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, alkenyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, or cyano; and

R13 and R17 are independently hydrogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, alkenyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, or cyano.

2. The compound according to claim 1 , wherein:

R11, R12, R14, R15, R16 and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, nitro, or cyano; and

R13 and R17 are independently hydrogen, hydroxyl, thiol, lower alkyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, nitro, or cyano.

3. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition according to claim 3 , wherein said composition is a liposomal formulation.

5. The compound according to claim 1 , wherein said compound is selected from:

6. The compound according to claim 5 , wherein said compound is selected from compounds: 44, 45, 46, or 53.

7. An anti-microbial composition comprising an effective amount of one or more compounds according to claim 1 , and a carrier, diluent or excipient.

8. The anti-microbial composition according to claim 7 , wherein said anti-microbial composition is for inhibiting the growth and/or proliferation of a drug-resistant bacterium and said one or more compounds have anti-bacterial activity.

9. The anti-microbial composition according to claim 8 , wherein said drug-resistant bacterium is methocillin-resistant Staphylococcus aureus cell or vancomycin-resistant Enterococcus.

10. The anti-microbial composition according to claim 7 , wherein said composition is a liposomal formulation.

11. The anti-microbial composition according to claim 7 , wherein said anti-microbial composition is formulated for incorporation into a cosmetic product, personal care product, cleanser, polish, paint, spray, soap, or detergent.

12. The anti-microbial composition according to claim 7 , wherein said anti-microbial composition is an anti-bacterial composition and said one or more compounds have anti-bacterial activity.

13. The anti-microbial composition according to claim 12 , wherein said anti-bacterial composition is capable of inhibiting the growth of one or more gram-positive bacteria.

14. The anti-microbial composition according to claim 12 , wherein said anti-bacterial composition is capable of inhibiting the growth of one or more bacteria selected from the group of: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus and Staphylococcus epidermidis.

15. The antimicrobial composition according to claim 7 , wherein said one or more compounds are selected from compounds: 44, 45, 46, 47, 52, or 53.

16. The antimicrobial composition according to claim 15 , wherein said one or more compounds are selected from compounds: 44, 45, 46, or 53.

17. The compound according to claim 1 , wherein:

R4 is hydrogen, lower alkyl or acyl;

R5, R6, R7, R8, and R9 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, lower alkenyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, heterocycle, nitro, or cyano; and

R10 is H, lower alkyl, alkenyl, alkynyl, aryl, or acyl.

18. The compound according to claim 1 , wherein:

R4 is hydrogen or acyl;

R5, R6, R7, R8, and R9 are independently hydrogen, halogen, lower alkyl, amino, carboxyl, or nitro; and

R10 is H, lower alkyl or acyl.

19. The compound according to claim 1 , wherein:

R4 is hydrogen;

R5, R6, R7, R8, and R9 are independently hydrogen, halogen, or lower alkyl; and

R10 is H or lower alkyl.

20. The compound according to claim 2 , wherein:

R11, R12, R14, R15, R16 and R18 are independently hydrogen or halogen; and R13 and R17 are hydrogen.

Assignments (5)
CHANGE OF NAME Recorded Sep 22, 2014
From: LORUS THERAPEUTICS INC.
To: APTOSE BIOSCIENCES INC.
Reel/Frame 033793/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2009
From: GENESENSE TECHNOLOGIES INC.
To: LORUS THERAPEUTICS INC.
Reel/Frame 022966/0151 →
CHANGE OF NAME Recorded Sep 7, 2007
From: LORUS THERAPEUTICS INC.
To: 4325231 CANADA INC.
Reel/Frame 019807/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2007
From: 4325231 CANADA INC.
To: GENESENSE TECHNOLOGIES INC.
Reel/Frame 019700/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2007
From: AL-QAWASMEH, RAED; YOUNG, AIPING H.; HUESCA, MARIO; LEE, YOON
To: LORUS THERAPEUTICS INC.
Reel/Frame 019401/0243 →
Priority Claims (1)
CA 2398765 · Aug 19, 2002 · national
Continuity (1)
Related Publication 20070105929A1 · May 10, 2007